SuperworthEnveric Biosciences ENVB
- Market cap
- $6.3M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1.3M−38% | $1.7M−9% | $506.2K−72% | $565K−76% | $802.7K−37% | $967.4K−44% | $746.4K+48% | $1.3M+123% | $402.4K−50% | $372.2K−62% | $346K−54% | $1.4M+8% |
| SG&A | $2.1M−41% | $578.7K−80% | $1.9M−36% | $1.2M−62% | $1.2M−43% | $2.1M+267% | $1.4M−28% | $1.2M−2% | $1.4M+20% | $1.8M−16% | $1.2M−8% | $1.6M+34% |
| −$3.4M−39% | −$2.4M−81% | −$2.5M−49% | −$1.9M−67% | −$2.1M−40% | −$3.2M+33% | −$2.2M−12% | −$2.5M+33% | −$1.9M−10% | −$2.2M−31% | −$1.6M−25% | −$3M+20% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$2.8M+14% | −$3.4M−66% | −$2.5M−48% | −$1.9M−70% | −$2.1M−26% | −$3.1M−8% | −$2.2M−11% | −$2.5M+34% | −$1.9M−10% | −$2.2M−30% | −$1.6M−25% | −$3M+20% |
| $6.6K | $22.3K | $1.7K | $0 | $0 | $7.2K−68% | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$2.8M+14% | −$3.4M−60% | −$2.5M−48% | −$1.9M−70% | −$2.1M−26% | −$3.2M−8% | −$2.2M−11% | −$2.5M+34% | −$1.9M−10% | −$2.2M−30% | −$1.6M−25% | −$3M+20% |
| −$15.60−11% | −$18.00−65% | −$110.52+299% | −$44.64+22% | −$43.10+176% | −$57.72+221% | −$14.58−87% | −$11.65−74% | −$10.81−75% | n/a | −$1.08−93% | −$0.76−94% | |
| 180.4K+21% | 190.3K+10% | 22.2K−87% | 42.2K−76% | 48.4K−73% | 54.7K−71% | 149.8K+574% | 216.3K+413% | 313.2K+548% | n/a | 1.5M+908% | 4M+1743% |
EPS, diluted: 15 periods, Q4 FY10 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 21 periods, Q2 FY10 to Q1 FY21: not printed by the filing, worked out from its own lines. 7 periods, Q4 FY15 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY16: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 274, the two on one basis (x15).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Enveric Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ENVBEnveric Biosciences | $6.3M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| Peer median | $47.8M | 13.6× | 14.8× | 1.4× | +15% | 7.6% |
More on Enveric Biosciences
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .